New York, NY: Dupilumab (Dupixent) significantly reduced exacerbations in patients aged 6 to <12 years with uncontrolled, moderate-to-severe asthma

Dupilumab helps reduce exacerbations in kids with moderate-to-severe asthma

submited by
Style Pass
2021-05-29 04:08:01

New York, NY: Dupilumab (Dupixent) significantly reduced exacerbations in patients aged 6 to <12 years with uncontrolled, moderate-to-severe asthma, show results from the VOYAGE study. Also, Dupilumab rapidly improved lung function within two weeks, an improvement that was sustained for up to 52 weeks (the length of the trial), compared to placebo.

Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4/interleukin-13, key and central drivers of type 2 inflammation in multiple diseases.

VOYAGE is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.

"We hope results from the VOYAGE trial will lay the groundwork for dupilumab as a potential new treatment option for patients aged 6 to 11 with moderate-to-severe asthma," said study author/investigator Leonard B. Bacharier, MD, professor of pediatrics, allergy/immunology/pulmonary medicine, Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center. "We also hope this study will lead to better characterization and understanding of the role of type 2 inflammation in asthma in pediatric patients."

Dupilumab has previously been shown to be effective and have a demonstrated safety profile in adolescents and adults with moderate-to-severe asthma, patients six years of age and older with moderate-to-severe atopic dermatitis, and adults with chronic rhinosinusitis with nasal polyposis.

Leave a Comment